To date, only nab-paclitaxel has been approved in combination with atezolizumab or pembrolizumab, mAbs targeted at PD-L1 and PD-1, respectively, for the treatment of breast cancer in Europe [2,3,146]. The gene discussed is CD274; the disease is breast carcinoma.